Gerd Mikus1, Kathrin I Foerster, Theresa Terstegen, Cathrin Vogt, André Said, Martin Schulz, Walter E Haefeli. 1. Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany; Cooperation Unit Clinical Pharmacy, Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany; Drug Commission of German Pharmacists (AMK), Berlin, Germany; Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.
Abstract
BACKGROUND: Five-day oral therapies against early COVID-19 infection have recently been conditionally approved in Europe. In the drug combination nirmatrelvir + ritonavir (nirmatrelvir/r), the active agent, nirmatrelvir, is made bioavailable in clinically adequate amounts by the additional administration of a potent inhibitor of its first-pass metabolism by way of cytochrome P450 [CYP] 3A in the gut and liver. In view of the central role of CYP3A in the clearance of many different kinds of drugs, and the fact that many patients with COVID-19 are taking multiple drugs to treat other conditions, it is important to assess the potential for drug interactions when nirmatrelvir/r is given, and to minimize the risks associated with such interactions. METHODS: We defined the interaction profile of ritonavir on the basis of information derived from two databases (Medline, GoogleScholar), three standard electronic texts on drug interactions, and manufacturer-supplied drug information. We compiled a list of drugs and their potentially relevant interactions, developed a risk min - imization algorithm, and applied it to the substances in question. We also compiled a list of commonly prescribed drugs for which there is no risk of interaction with nirmatrelvir/r. RESULTS: Out of 190 drugs and drug combinations, 57 do not need any special measures when given in combination with brief, low-dose ritonavir treatment, while 15 require dose modification or a therapeutic alternative, 8 can be temporarily discontinued, 9 contraindicate ritonavir use, and 102 should preferably be combined with a different treatment. CONCLUSION: We have proposed measures that are simple to carry out for the main types of drug that can interact with ritonavir. These measures can be implemented under quarantine conditions before starting a 5-day treatment with nirmatrelvir/r.
BACKGROUND: Five-day oral therapies against early COVID-19 infection have recently been conditionally approved in Europe. In the drug combination nirmatrelvir + ritonavir (nirmatrelvir/r), the active agent, nirmatrelvir, is made bioavailable in clinically adequate amounts by the additional administration of a potent inhibitor of its first-pass metabolism by way of cytochrome P450 [CYP] 3A in the gut and liver. In view of the central role of CYP3A in the clearance of many different kinds of drugs, and the fact that many patients with COVID-19 are taking multiple drugs to treat other conditions, it is important to assess the potential for drug interactions when nirmatrelvir/r is given, and to minimize the risks associated with such interactions. METHODS: We defined the interaction profile of ritonavir on the basis of information derived from two databases (Medline, GoogleScholar), three standard electronic texts on drug interactions, and manufacturer-supplied drug information. We compiled a list of drugs and their potentially relevant interactions, developed a risk min - imization algorithm, and applied it to the substances in question. We also compiled a list of commonly prescribed drugs for which there is no risk of interaction with nirmatrelvir/r. RESULTS: Out of 190 drugs and drug combinations, 57 do not need any special measures when given in combination with brief, low-dose ritonavir treatment, while 15 require dose modification or a therapeutic alternative, 8 can be temporarily discontinued, 9 contraindicate ritonavir use, and 102 should preferably be combined with a different treatment. CONCLUSION: We have proposed measures that are simple to carry out for the main types of drug that can interact with ritonavir. These measures can be implemented under quarantine conditions before starting a 5-day treatment with nirmatrelvir/r.
Authors: D J Greenblatt; L L von Moltke; J S Harmatz; A L Durol; J P Daily; J A Graf; P Mertzanis; J L Hoffman; R I Shader Journal: Clin Pharmacol Ther Date: 2000-04 Impact factor: 6.875
Authors: Christopher Heeschen; Christian W Hamm; Ulrich Laufs; Steven Snapinn; Michael Böhm; Harvey D White Journal: Circulation Date: 2002-03-26 Impact factor: 29.690
Authors: K Venkatakrishnan; J Schmider; J S Harmatz; B L Ehrenberg; L L von Moltke; J A Graf; P Mertzanis; K E Corbett; M C Rodriguez; R I Shader; D J Greenblatt Journal: J Clin Pharmacol Date: 2001-10 Impact factor: 3.126
Authors: David J Greenblatt; Diane E Peters; Lauren E Oleson; Jerold S Harmatz; Malcolm W MacNab; Noah Berkowitz; Miguel A Zinny; Michael H Court Journal: Br J Clin Pharmacol Date: 2009-12 Impact factor: 4.335
Authors: Olaf Schouten; Sanne E Hoeks; Gijs M J M Welten; Jean Davignon; John J P Kastelein; Radosav Vidakovic; Harm H H Feringa; Martin Dunkelgrun; Ron T van Domburg; Jeroen J Bax; Don Poldermans Journal: Am J Cardiol Date: 2007-05-22 Impact factor: 2.778
Authors: Hanna Kaduszkiewicz; Michael M Kochen; Stefan Kluge; Jakob J Malin; Stephanie Weibel; Nicole Skoetz Journal: Dtsch Arztebl Int Date: 2022-05-13 Impact factor: 8.251
Authors: Stefan R Bornstein; Diana Cozma; Margrit Kamel; Mawieh Hamad; Mohammad G Mohammad; Naveed A Khan; Maha M Saber; Mohammad H Semreen; Charlotte Steenblock Journal: Horm Metab Res Date: 2022-06-20 Impact factor: 2.788